Header Logo

Connection

Usman Baber to Myocardial Infarction

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Myocardial Infarction.
Usman Baber
Connection Strength
7.077
Myocardial Infarction
  1. Variability in low-density lipoprotein cholesterol and cardiovascular risk: should consistency be a new target? J Am Coll Cardiol. 2015 Apr 21; 65(15):1549-51.
    View in: PubMed
    Score: 0.397
  2. DAPT duration after DES: what is the "mandatory" duration? J Am Coll Cardiol. 2015 Mar 24; 65(11):1103-6.
    View in: PubMed
    Score: 0.395
  3. Mortality After Procedural or Spontaneous Myocardial Infarction. J Am Coll Cardiol. 2024 Jul 30; 84(5):467-477.
    View in: PubMed
    Score: 0.189
  4. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023 11 16; 383:e077848.
    View in: PubMed
    Score: 0.180
  5. Timing and Predictors of Myocardial Infarction or Stent Thrombosis in High-Bleeding Risk Patients Undergoing PCI. JACC Cardiovasc Interv. 2023 06 26; 16(12):1558-1560.
    View in: PubMed
    Score: 0.175
  6. Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023 04 10; 9(3):240-250.
    View in: PubMed
    Score: 0.173
  7. Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease. Catheter Cardiovasc Interv. 2023 02; 101(3):511-519.
    View in: PubMed
    Score: 0.170
  8. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
    View in: PubMed
    Score: 0.168
  9. Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Can J Cardiol. 2022 06; 38(6):792-800.
    View in: PubMed
    Score: 0.159
  10. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
    View in: PubMed
    Score: 0.158
  11. Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. J Thromb Thrombolysis. 2022 Feb; 53(2):380-389.
    View in: PubMed
    Score: 0.154
  12. Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. J Thromb Thrombolysis. 2022 Jan; 53(1):20-29.
    View in: PubMed
    Score: 0.154
  13. Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. Am J Cardiol. 2021 06 01; 148:165-171.
    View in: PubMed
    Score: 0.149
  14. Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention. 2020 Jun 25; 16(3):218-224.
    View in: PubMed
    Score: 0.142
  15. One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. Catheter Cardiovasc Interv. 2021 06 01; 97(7):1341-1351.
    View in: PubMed
    Score: 0.142
  16. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. J Am Heart Assoc. 2020 04 21; 9(8):e015865.
    View in: PubMed
    Score: 0.140
  17. Association between age and readmission after percutaneous coronary intervention for acute myocardial infarction. Heart. 2020 10; 106(20):1595-1603.
    View in: PubMed
    Score: 0.139
  18. Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large single-center registry. Catheter Cardiovasc Interv. 2020 09 01; 96(3):E278-E286.
    View in: PubMed
    Score: 0.139
  19. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.138
  20. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circ Cardiovasc Interv. 2019 07; 12(7):e007734.
    View in: PubMed
    Score: 0.133
  21. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.132
  22. Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. Int J Cardiol. 2019 07 15; 287:59-61.
    View in: PubMed
    Score: 0.130
  23. Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. Am J Cardiol. 2019 06 15; 123(12):1941-1948.
    View in: PubMed
    Score: 0.130
  24. Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):E67-E77.
    View in: PubMed
    Score: 0.130
  25. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.127
  26. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2018 Nov; 118(11):1997-2005.
    View in: PubMed
    Score: 0.126
  27. Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry. Am Heart J. 2019 01; 207:10-18.
    View in: PubMed
    Score: 0.126
  28. Prognostic Relation Between Severity of Diabetes Mellitus (On or Off Insulin)?±?Chronic Kidney Disease with Cardiovascular Risk After Percutaneous Coronary Intervention. Am J Cardiol. 2018 01 15; 121(2):168-176.
    View in: PubMed
    Score: 0.118
  29. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.116
  30. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol. 2017 08 01; 2(8):855-862.
    View in: PubMed
    Score: 0.116
  31. Improving Outcomes in High-Risk Percutaneous Coronary Interventions and Newer-Generation Drug-Eluting Stents: Good, But Not Good Enough. Cardiology. 2017; 138(2):73-75.
    View in: PubMed
    Score: 0.115
  32. Quantitative angiographic characterisation of coronary artery disease in patients with human immunodeficiency virus (HIV) infection undergoing percutaneous coronary intervention. EuroIntervention. 2017 Feb 20; 12(14):1757-1765.
    View in: PubMed
    Score: 0.113
  33. Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. Am J Cardiol. 2017 04 15; 119(8):1166-1172.
    View in: PubMed
    Score: 0.112
  34. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.108
  35. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis. Circ Cardiovasc Interv. 2016 Jan; 9(1):e002995.
    View in: PubMed
    Score: 0.104
  36. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016 Jan; 171(1):40-7.
    View in: PubMed
    Score: 0.101
  37. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 15; 116(6):845-52.
    View in: PubMed
    Score: 0.101
  38. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015 Jun; 8(7):937-45.
    View in: PubMed
    Score: 0.100
  39. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv. 2013 Oct 01; 6(5):507-17.
    View in: PubMed
    Score: 0.089
  40. Comparison of six risk scores in patients with triple vessel coronary artery disease undergoing PCI: competing factors influence mortality, myocardial infarction, and target lesion revascularization. Catheter Cardiovasc Interv. 2013 Nov 15; 82(6):855-68.
    View in: PubMed
    Score: 0.088
  41. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2012 Dec; 5(12):1231-8.
    View in: PubMed
    Score: 0.084
  42. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.080
  43. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial. Circ Cardiovasc Interv. 2012 Apr; 5(2):157-65.
    View in: PubMed
    Score: 0.080
  44. Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2011 Oct 18; 58(17):1750-6.
    View in: PubMed
    Score: 0.078
  45. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011 Oct 04; 58(15):1569-77.
    View in: PubMed
    Score: 0.077
  46. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.069
  47. Thrombolysis In Myocardial Infarction (TIMI) risk score and mortality in patients with advanced chronic kidney disease and on dialysis. Am J Cardiol. 2009 Jun 01; 103(11):1513-7.
    View in: PubMed
    Score: 0.065
  48. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
    View in: PubMed
    Score: 0.042
  49. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ. 2021 06 16; 373:n1332.
    View in: PubMed
    Score: 0.038
  50. One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration. Cardiovasc Drugs Ther. 2021 04; 35(2):309-320.
    View in: PubMed
    Score: 0.037
  51. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
    View in: PubMed
    Score: 0.034
  52. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.033
  53. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019 05 21; 73(19):2401-2409.
    View in: PubMed
    Score: 0.033
  54. Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheter Cardiovasc Interv. 2019 05 01; 93(6):1124-1131.
    View in: PubMed
    Score: 0.032
  55. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.029
  56. Mid-term outcomes of consecutive 998 cases of coronary atherectomy in contemporary clinical practice. J Interv Cardiol. 2017 Aug; 30(4):331-337.
    View in: PubMed
    Score: 0.029
  57. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.028
  58. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.028
  59. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
    View in: PubMed
    Score: 0.028
  60. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JACC Cardiovasc Interv. 2016 09 26; 9(18):1890-901.
    View in: PubMed
    Score: 0.027
  61. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.027
  62. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.027
  63. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016 Apr 11; 9(7):674-84.
    View in: PubMed
    Score: 0.027
  64. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 09 06; 68(10):1116-39.
    View in: PubMed
    Score: 0.026
  65. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. Catheter Cardiovasc Interv. 2016 Mar; 87(4):703-9.
    View in: PubMed
    Score: 0.026
  66. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015 Apr 07; 65(13):1298-1310.
    View in: PubMed
    Score: 0.024
  67. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention. 2014 Jul; 10(3):312-9.
    View in: PubMed
    Score: 0.023
  68. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol. 2014 Jun; 62(3):261-76.
    View in: PubMed
    Score: 0.023
  69. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013 Dec 07; 382(9908):1879-88.
    View in: PubMed
    Score: 0.022
  70. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013 Nov 23; 382(9906):1714-22.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.